The REPEAT Trial: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma, a Phase 1b Study
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Regorafenib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms REPEAT
- 12 Sep 2017 Results (n=14) presented at the 42nd European Society for Medical Oncology Congress.
- 26 Jul 2016 Planned End Date changed from 1 Apr 2018 to 1 Mar 2018.
- 26 Jul 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.